Patients with DR and/or DME face significant lifelong challenges including potential blindness, but may not be aware of the financial help available to them to ensure compliance with their treatments.
Patient adherence to treatment can sometimes be tricky—especially when out-of-pocket costs are considered.
And because patients with diabetic macular edema (DME) or diabetic retinopathy (DR) are likely to have other complications from their systemic disease, for some patients prioritizing other medications over intravitreal injections is an easy choice.
Unfortunately, it’s also not uncommon to determine the reason patients miss their eye care appointments is because other complications of their systemic disease take precedence.
Because of the significant financial burden that patients with DR and/or DME experience, a number of pharmaceutical companies have created patient assistance programs to help alleviate the economic burden.
In alphabetical order:
Alimera Sciences, for example, offers financial assistance for Iluvien (fluocinolone acetonide intravitreal implant) through its AccessPlus program. Like Genentech and Regeneron, Alimera offers patients a Co-Pay Program that provides financial assistance for commercially insured patients with out-of-pocket expenses that exceed $25. Patients must be U.S. resident and not on a government insurance program. Patients who are accepted into the program will pay up to $25 per Iluvien injection. Patients on Medicare and Medicare Advantage will be referred to an independent co-pay foundation. AccessPlus support staff will help patients find foundations that are right for them and guide them through the application process.